
Press Releases
Presentations
CHDI 2022: SHIELD HD – A Natural History Study to Support Clinical and Biomarker Development
In the News
Media contact
Eric Sullivan
Triplet Therapeutics
esullivan@triplettx.com
Eric Sullivan
Triplet Therapeutics
esullivan@triplettx.com